Houston business attorneys can help local companies fend off spurious lawsuits

by Stibbs & Co., P.C. on December 17, 2012

Houston-based SITA Oil Exploration House forged the "guarantee" documents now at the center of a lawsuit brought against Amegy Bank of Texas by Thailand's Minister of Energy, the bank's lawyers alleged in Harris County Court.

Amegy is suing SITA and its owner, Sawapam Bhattacharjee, in connection with the fraud. In court, the bank's attorneys asserted that the oil field drilling company submitted bids to Thailand's government in an attempt to receive concessions that would allow it to explore for oil in the country.

"As part of the bidding process,

View the Original article

Energy Companies no Proxy for ISX

KRG Investment Board Chair visits Austria, Slovakia Maliki meets US Deputy Secretary for Resources Advancing Iraq’s Unfinished Constitutional Agenda New Date for Anbar Investment Commission Conference Categorized

View the Original article

Higher demand drives Indian oil companies fight for foreign assets

State-run ONGC Videsh has agreed to pay about $ 5 billion for 8.4 percent of the Kashagan field in Kazakhstan. Reuters

The deal is added to a stable of assets that span some of the most difficult areas in the world

View the Original article

Houston-based Pernix Therapeutics acquires two pharmaceutical companies

by Stibbs & Co., P.C. on November 14, 2012

While the Houston oil and gas industry does play a major role in this city's growing economy, companies in other industries are also enjoying expansion. Mergers and acquisitions can help push forward a company's pursuits and one Houston-based firm has recently announced a purchase that may ensure its continued success in the region.

The Houston Business Journal reported that Pernix Therapeutics Holdings Inc. has acquired two Mississippi-based pharmaceutical companies for approximately $101 million. The CEO of Pernix, Cooper Collins, said that this is the "most significant acquisition" his firm has conducted in its entire history.

The purchase includes Cypress Pharmaceuticals and Hawthorn Pharmaceuticals, which encompass a total of 170 employees with revenue passing $50 million this year. The deal will be completed by the end of 2012.

"The generic and branded businesses of Cypress and Hawthorn are an excellent fit for Pernix, which is expected to increase the company's revenues for the full year 2013 to approximately $135

View the Original article